(NASDAQ:VBLT) is now down by 8.33% at $6.60 giving up $0.60 . 300,976 shares have changed hands.
The stock is trading at $6.60 which is quite a bit above the 50 day moving average of $4.93 and which is significantly higher than the 200 day moving average of $5.16. The 50 day moving average was up by +33.97% whereas the 200 day moving average was up $1.44 or +27.79%.
Short traders are feeling a little more bearish on Vascular Biogenics Ltd. – Ordin recently as evidenced by the increase in short interest. The firm had a rise in short interest of 45.92% as of August 31, 2017 from the last reporting period. Short interest grew from 291,724 to 425,681 over that period. Days to cover increased from 3.0 to 5.0 and the short interest percentage is 0.02% as of August 31.
Additionally, here are a few investment firms who have increased or decreased their stake in (VBLT). As of the end of the quarter Tower Research Capital LLC (trc) had bought a total of 1,914 shares growing its position 957.0%. The value of the investment in VBLT increased from $1,000 to $9,000 a change of $8,000 since the last quarter. As of quarter end First Eagle Investment Management, LLC had disposed of 236,756 shares trimming its stake by 26.5%. The value in dollars went from $4,908,000 to $2,917,000 decreasing 40.6% quarter to quarter.
As of quarter end Migdal Insurance & Financial Holdings Ltd. had sold 3,274 shares trimming its holdings by 0.8%. The value of the total investment in Vascular Biogenics Ltd. – Ordin decreased from $2,200,000 to $1,765,000 a change of 19.8% quarter over quarter. As of quarter end Menta Capital LLC had sold 22,000 shares trimming its position 18.0%. The value of the investment in (VBLT) decreased from $671,000 to $445,000 a change of $226,000 for the reporting period.
As of the last earnings report the EPS was $-0.67 and is projected to be $-0.74 for the current year with 27,009,000 shares currently outstanding. Analysts expect next quarter’s EPS will be $-0.19 with next year’s EPS projected to be $-0.78.
Vascular Biogenics Ltd., launched on January 31, 2000, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Business’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is involved in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule that demonstrated efficacy in reducing vascular inflammation in a Phase II sub-study in psoriatic patients with cardiovascular risk..